Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ALKS |
---|---|---|
09:32 ET | 11467 | 24.15 |
09:34 ET | 2430 | 24.24 |
09:36 ET | 3218 | 24.1 |
09:38 ET | 700 | 24.135 |
09:39 ET | 450 | 24.19 |
09:41 ET | 2777 | 24.195 |
09:43 ET | 300 | 24.175 |
09:45 ET | 12562 | 24.22 |
09:48 ET | 4567 | 24.15 |
09:50 ET | 700 | 24.13 |
09:52 ET | 2112 | 24.13 |
09:54 ET | 2077 | 24.12 |
09:56 ET | 1241 | 24.105 |
09:57 ET | 2143 | 24.105 |
09:59 ET | 2650 | 24.11 |
10:01 ET | 1826 | 24.13 |
10:03 ET | 9550 | 24.1 |
10:06 ET | 1405 | 24.15 |
10:08 ET | 4242 | 24.14 |
10:10 ET | 1100 | 24.1 |
10:12 ET | 3321 | 24.1 |
10:14 ET | 741 | 24.09 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Alkermes Plc | 4.1B | 6.9x | --- |
Exelixis Inc | 6.5B | 34.3x | -21.77% |
PTC Therapeutics Inc | 2.7B | -4.5x | --- |
P3 Health Partners Inc | 175.4M | -0.9x | --- |
Novavax Inc | 2.0B | -4.3x | --- |
Qiagen NV | 9.1B | 27.1x | +12.66% |
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $4.1B |
---|---|
Revenue (TTM) | $1.7B |
Shares Outstanding | 169.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.44 |
EPS | $3.50 |
Book Value | $7.20 |
P/E Ratio | 6.9x |
Price/Sales (TTM) | 2.4 |
Price/Cash Flow (TTM) | 6.2x |
Operating Margin | 29.25% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.